Thermo Fisher Scientific Inc (TMO) Key Developments | Reuters.com
Edition:
United States

Thermo Fisher Scientific Inc (TMO)

TMO on New York Consolidated

143.15USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$143.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,497,017
52-wk High
$154.81
52-wk Low
$117.10

Latest Key Developments (Source: Significant Developments)

Strata Oncology completes series A financing
Wednesday, 1 Jun 2016 08:00am EDT 

:Strata Oncology completes series A financing and signs strategic partnership with Thermo Fisher Scientific.  Full Article

Thermo Fisher to acquire FEI Company for $4.2 bln
Friday, 27 May 2016 07:00am EDT 

Thermo Fisher Scientific Inc : Thermo fisher scientific to acquire FEI Company . Deal for $4.2 billion . Deal for $107.50 per share in cash . Deal expected to be immediately accretive to adjusted earnings per share . Thermo Fisher expects to realize total synergies of about $80 million by year three following close of deal . Transaction is expected to be accretive to Thermo Fisher's adjusted EPS by $0.30 in first full year after close . JP Morgan is acting as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel . Expects to realize total synergies of approximately $80 million by year three following close of deal .Intends to use proceeds from committed debt financing and cash on hand to fund transaction..  Full Article

Enzo Biochem reaches settlement with unit of Thermo Fisher
Monday, 16 May 2016 04:07pm EDT 

Enzo Biochem Inc : Settlement does not affect unit's action brought in federal district court in new haven, ct against life technologies' predecessors . Settlement resolves dispute between enzo life sciences and life technologies impacts only one of 11 cases originally brought by enzo . Resolved suit is one of 11 infringement cases brought in delaware federal district court; seven remain pending .Enzo biochem's life sciences unit reaches $35 million patent infringement settlement in delaware with life technologies corporation.  Full Article

Thermo Fisher Scientific Inc raises FY 2016 guidance
Thursday, 28 Apr 2016 06:00am EDT 

Thermo Fisher Scientific Inc:Raises its revenue and adjusted EPS guidance for FY 2016 to reflect inclusion of Affymetrix results for nine months, a less adverse foreign exchange environment, additional stock buybacks completed in the first quarter and stronger operational performance.Raises revenue guidance to new range of $17.86 to $18.04 billion versus its original guidance of $17.36 to $17.56 billion announced in Jan. 2016.Raises adjusted EPS guidance to a new range of $8.05 to $8.19 versus the $7.80 to $7.96 previously communicated, for 9 to 11 percent growth over FY 2015.  Full Article

Thermo Fisher Scientific Inc prices offering of senior notes
Monday, 4 Apr 2016 05:30pm EDT 

Thermo Fisher Scientific Inc:Says priced an offering of $1.0 billion aggregate principal amount of 3.000% senior notes due 2023 at an issue price of 99.512% of the principal amount.Says Issuance of the notes is expected to close on or about April 13, 2016.Plans to use the net proceeds of the offering and cash on hand to redeem all of the outstanding $1.0 billion aggregate principal amount of its 2.250% senior notes that mature on August 15, 2016.Joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith Incorporated; Goldman, Sachs & Co. and Morgan Stanley & Co. LLC.  Full Article

Thermo Fisher Scientific Declares Quarterly Dividend
Thursday, 25 Feb 2016 08:30am EST 

Thermo Fisher Scientific Inc:declared a quarterly cash dividend of $0.15 per share.The dividend will be paid on April 15, 2016, to shareholders of record as of March 15, 2016.  Full Article

Thermo Fisher Scientific to acquire Affymetrix
Friday, 8 Jan 2016 05:46pm EST 

Thermo Fisher Scientific Inc:Transaction represents a purchase price of about $1.3 billion.Deal for $14.00 per share.Says deal expected to be immediately accretive to adjusted earnings per share.Expects to realize total synergies of approximately $70 million by year three following the close.Says Thermo Fisher intends to use cash on hand and short-term debt to finance the transaction.JP Morgan is acting as financial advisor to Thermo Fisher.Transaction expected to be immediately accretive to adjusted EPS, adding $0.10 of accretion in first full year of ownership.Boards of directors have unanimously approved Thermo fisher's acquisition of Affymetrix.  Full Article

Thermo Fisher Scientific Inc prices offering of senior notes
Monday, 30 Nov 2015 05:24pm EST 

Thermo Fisher Scientific Inc:Prices offering of senior notes.Says priced an offering of $450 million aggregate principal amount of 2.150% senior notes due 2018.Says notes will pay interest on a semi-annual basis.Priced $350 million amount of 3.650% senior notes due 2025 at an issue price of 99.858% of the principal amount.Priced offering of $450 million of senior notes at an issue price of 99.997% of the principal amount.  Full Article

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
Friday, 13 Nov 2015 04:05pm EST 

Thermo Fisher Scientific Inc:Says it has priced an offering of EUR425 million aggregate principal amount of 1.50% senior notes due 2020 at an issue price of 99.971% of.principal amount.issuance of the notes is expected to close on or about November 24, 2015, subject to customary closing conditions.notes will pay interest on an annual basis.plans to use portion of the net proceeds of offering to redeem all of outstanding $400 mln aggregate principal amount of 3.50% senior notes issued by Life Technologies Corporation, which mature on January 15, 2016, and remainder for general corporate purposes.joint book-running managers for the offering are Deutsche Bank AG, London Branch and HSBC Bank plc.  Full Article

Thermo Fisher Scientific Inc authorizes $1 billion of share repurchases and declares quarterly dividend
Thursday, 12 Nov 2015 04:30pm EST 

Thermo Fisher Scientific Inc:Authorized the repurchase of $1 billion of shares of its common stock in the open market or in negotiated transactions.New share repurchase authorization replaces the existing authorization, in which there was approximately $410 million remaining.Intends to resume share repurchases in 2016.Declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on January 15, 2016, to shareholders of record as of December 15, 2015.  Full Article

BRIEF-Adaptimmune says enters commercial development and supply agreement with Thermo Fisher

* Adaptimmune announces commercial development and supply agreement for Thermo Fisher scientific's Dynabeads cd3/cd28 cell therapy system